Work

Final Results of a CTEP Sponsored Phase I Study of Alistertib in Combination with Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma

Year: 2018

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2018-99-116991

Authors: Stefan Klaus Barta, Noah Kornblum, Bruce G. Raphael, Kenneth B. Hymes, Michael L. Grossbard, Tibor Moskovits, Elizabeth Handorf, Joseph Sparano, Richard Piekarz, Catherine Diefenbach

Institutions: Fox Chase Cancer Center, Albert Einstein College of Medicine, Montefiore Medical Center, Montefiore Einstein Comprehensive Cancer Center, NYU Langone Health, National Institutes of Health, National Cancer Institute, NYU Langone’s Laura and Isaac Perlmutter Cancer Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2914849598

Cites:

Cited by:

Related to: 10